Clinical trial
Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome…
NCT00094172 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00094172 |
|---|---|
| Title | Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients With Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (ITN020AI) |
| Acronym | STAYCIS |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Immune Tolerance Network (ITN) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Atorvastatin, Placebo |
| Enrollment | 82 |
| Start date | May 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Oct 15, 2004 |
| Last update posted | Apr 28, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: